A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C

• Robert Flisiak,

  Affiliation Department of Infectious Diseases and Hepatology, Medical University of Bialystock, Bialystock, Poland

  ⨯
• Mitchell Shiffman,

  Affiliation Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States of America

  ⨯
• Juan Arenas,

  Affiliation Department of Gastroenterology and Hepatology, University Hospital Donostia, San Sebastián, Spain

  ⨯
• Hugo Cheinquer,

  Affiliation Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

  ⨯
• Igor Nikitin,

  Affiliation Department of Higher Level General Medicine, Russian State Medical University, Moscow, Russia

  ⨯
• Yuping Dong,

  Affiliation Research and Development, Bristol-Myers Squibb, Inc., Wallingford, Connecticut, United States of America

  ⨯
• Khurram Rana,

  Affiliation Research and Development, Bristol-Myers Squibb, Inc., Wallingford, Connecticut, United States of America

  ⨯
• Subasree Srinivasan

  * E-mail: subasree@sbcglobal.net

  Affiliation Research and Development, Bristol-Myers Squibb, Inc., Wallingford, Connecticut, United States of America

  ⨯